Contact The Editorial Desk

Editorial correspondence

This site welcomes correspondence on the research record: a citation quoted inaccurately, a trial that has since published new results, a regulatory status update, or a peer-reviewed study on GHK-Cu, KPV, semaglutide, or tirzepatide that belongs on the references page. This is the single most useful category of message this desk receives, and every one is read.

The most actionable submissions name the page in question, quote the exact passage being challenged, and include the supporting source — a DOI or PubMed identifier wherever possible, so the proposed change can be verified before anything is edited.

Editorial mailbox: editors@peptidetestimonials.com

What this desk cannot do

So that no message goes unanswered for the wrong reason, a few things fall outside what this site handles. It is a literature digest, not a clinical service or a product vendor, so it cannot advise on or recommend human use of any compound discussed here, suggest a dose or route of administration for any individual, judge whether a cited finding applies to a specific person's situation, or sell, source, or help locate any compound from any supplier.

Semaglutide and tirzepatide are prescription medicines available only through a licensed provider. GHK-Cu beyond topical cosmetic use, and KPV in any form, have no established human safety basis. Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.